Inotek Pharmaceuticals
Manufacturing · Massachusetts, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
131 Hartwell Ave Ste 1 Ste 105, Lexingto...Phone Number
(781) 676-2100Website
www.inotekpharma.comRevenue
$7.8 MillionIndustry
ZI Rank: 1
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
1
1
1
1
1
1
About Inotek Pharmaceuticals
Inotek Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of therapies for glaucoma and other eye diseases. The Company's lead product candidate, trabodenoson, is a first-in-class selective adenosine mimetic currently in Phase 3 development. Trabodenoson was developed in Inotek's laboratories and is designed to restore the eye's natural pressure control mechanism. Additionally, the Company is evaluating the potential for selective adenosine mimetics to address optic neuropathies and other degenerative retinal diseases.Explore more
Inotek Pharmaceuticals Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Inotek Pharmaceuticals your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Website visits: Recent activity has been detected on your website
Check out if Inotek Pharmaceuticals is spiking on competitors!
Earning: See what the market has to say on Inotek Pharmaceuticals recently announced quarterly report
Check if Inotek Pharmaceuticals has recently received funding, and reach out quickly before it becomes old news!
Congratulate Masked Content for being promoted to Masked Content at Inotek Pharmaceuticals
Product Launch: Get notified when Inotek Pharmaceuticals launches new products
Funding: Get notified immidiatlly once Inotek Pharmaceuticals has new funding data
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Inotek Pharmaceuticals, which may be a good buyer, showed buying intent in Masked Content Topic
Click to see if Inotek Pharmaceuticals had a recent Job posting/layoffs
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find more new buyers
Compare Similar Companies to Inotek Pharmaceuticals
Compare insights from companies similar to Inotek Pharmaceuticals, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Inotek Pharmaceuticals
$7.8M
11-50
Private
$40M
1996
CB
Chaim BrickmanSenior Medical Director, Clinical Development & Pharmacovigilance
Company Profile Activity
Activity Insights
Inotek Pharmaceuticals is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Inotek Pharmaceuticals is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Inotek Pharmaceuticals.
Inotek Pharmaceuticals financials insights
Gather financial insights about Inotek Pharmaceuticals, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2015
Stock Offering
$40M
Inotek Pharmaceuticals Tech Stack
A closer look at the technologies used by Inotek Pharmaceuticals
See more technologies
Inotek Pharmaceuticals News & Media
Rocket Pharmaceuticals Reports Full Year 2017 Financial Results and Operational Highlights
- Enters 2018 as a Public Company with Solid Financial Position Following Successful Completion of Merger with Inotek Pharmaceuticals and Subsequent Follow-on Offering - - Multiple Milestones Expected in 2018, with Additional Data in Fanconi Anemia, Disclosure of AAV Program, and Several Programs Advancing Toward the Clinic - NEW YORK--(BUSINESS WIRE)--Mar. 6, 2018-- Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) (“Rocket”), a leading U.S.-based multi-platform gene therapy company, today reported fiRocket Pharmaceuticals to Present at the Cowen & Company 38th Annual Health Care Conference
NEW YORK--(BUSINESS WIRE)--Mar. 5, 2018-- Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) (“Rocket”), a leading U.S.-based multi-platform gene therapy company, today announced that Gaurav Shah, M.D., Chief Executive Officer and President of Rocket, will present at the Cowen & Company 38th Annual Health Care Conference on Monday, March 12th, 2018, at 2:50 p.m. Eastern Time (ET). A live audio webcast of the presentation will be available on the Investors section of the company's website, www.rocketpharHercules Capital Announces Fourth Quarter and Full-Year 2017 Financial Results and Quarterly Distribution of $0.31 per Share
PALO ALTO, Calif.--(BUSINESS WIRE)--Hercules Capital, Inc. (NYSE: HTGC) (“Hercules” or the “Company”), the leading specialty financing provider to innovative venture growth stage companies backed by leading venture capital firms, today announced its financial results for the fourth quarter and fiscal-year ended December 31, 2017. The Company announced that its Board of Directors has declared a fourth quarter cash distribution of $0.31 per share, that will be payable on March 12, 2018, to sharehRocket Pharmaceuticals Announces Participation in a Fireside Chat at the Leerink Partners 7th Annual Global Healthcare Conference
NEW YORK--(BUSINESS WIRE)--Feb. 7, 2018-- Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) (“Rocket”), a leading U.S.-based multi-platform gene therapy company, today announced that Gaurav Shah, M.D., Chief Executive Officer and President of Rocket, will participate in a fireside chat at the Leerink Partners 7th Annual Global Healthcare Conference in New York City. The fireside chat will take place on Wednesday, February 14, 2018, at 2:00 p.m. Eastern Time (ET). About Rocket Pharmaceuticals, Inc. Roc
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Inotek Pharmaceuticals
Sign Up For FreeTo access detailed company insights
Inotek Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of therapies for glaucoma and other eye diseases. The Company's lead product candidate, trabodenoson, is a first-in-class selective adenosine mimetic currently in Phase 3 development. Trabodenoson was developed in Inotek'... Read More
